VAPO Release from this morning: Second Quarter Ending June

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
VAPO Release from this morning:
Second Quarter Ending June 30, 2014
Gross Profit Margins Improve to 43.2% for the 2014 Second Quarter as Compared to 36.8% for the 2014 First Quarter
Marketwired
Vaporin, Inc. 2 hours ago

MIAMI, FL--(Marketwired - Aug 11, 2014) - Vaporin, Inc. (OTCQB: VAPO), a distributor and marketer of electronic cigarettes, vaporizers and e-liquids products, today announced its financial results for the second quarter and six month period ending June 30, 2014.

Financial Highlights for the 2014 Three and Six Month Periods:

Revenue for the first six months of 2014 totaled $602,000;
Revenue for the second quarter of 2014 increased 130% to $419,000 as compared to $182,000 for the first quarter of 2014;
Growth sequentially was driven predominantly by an increase in convenience store distribution which increased over 300% and online sales which increased 10X;
Gross profit margins improved to 43.2% for the second quarter of 2014 as compared to 36.8% for the first quarter of 2014;
Gross profit margin improvement was driven by preferred product pricing, product volume increase and direct to consumer sales via online marketing.

"We are extremely pleased with our 2014 second quarter sales growth and margin expansion as we continue to focus our strategy on building distribution of our vaporizers through brick and mortar retailers, online promotion and vending machines. During the quarter our c-store distribution tripled and internet sales increased tenfold." Scott Frohman, Chief Executive Officer of Vaporin, continued, "According to Bonnie Herzog, Senior Beverage and Tobacco Analyst at Wells Fargo Securities, the vapors, tanks and mods industry has grown to $1.1 billion of the current $2.5 billion total addressable market for alternatives to combustible cigarettes. Additionally, vapor consumption is believed to surpass combustible cigarettes in the next decade. Vaporizers offer a better quality and consumer experience, stronger batteries and coils, a more satisfying hit, and the ability to mix and match flavors. We have established ourselves within this burgeoning industry with a growing brand, distribution, multiple revenue streams and a superior product base. We anticipate the traction we have gained thus far in 2014 to continue throughout the remainder of the year and heading into 2015."

Operational Highlights during the First Half of 2014:

Entered into the medical cannabis industry through an exclusive distribution agreement with Terra Tech Corp. (OTCQB: TRTC) to supply proprietary vaporizer products for resale throughout their cannabis dispensary network in California, Colorado, Washington and Oregon;
Signed an exclusive distribution agreement with Seaga Manufacturing, Inc. for the marketing and sale of goods through a unique, innovative vending solution, the Vapestation;
Deployed its first electronic cigarette vending machine during the second quarter of 2014;
Secured exclusive supply agreement with ChromaDex®, an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies, for the development of NIAGEN™ and PURENERGY™, novel ingredients with multiple energy and health benefits;
James J. Martin has been appointed as Chief Financial Officer of the Company; and,
Completion of merger, name change and trading under new stock symbol "VAPO".

About Vaporin, Inc.
Vaporin is a distributor and marketer of electronic cigarettes, vaporizers, and e-liquids products. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin is offered in a variety of disposable and rechargeable starter kits and flavors. The unique Vaping Pens product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, www.vaporin.com.

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements including statements regarding the continued growth of our business. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the results of our marketing efforts including our online initiative, competition from other e-cig. companies and the major tobacco companies and new regulations which affect the distribution of these products. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Contact:
Company
Vaporin, Inc.
Scott Frohman
Chief Executive Officer
305.842.2813
Email Contact

Investor Relations
Capital Markets Group, LLC
Valter Pinto
PH: (914) 669-0222 x201 or (212) 398-3486
Email Contact

Read More: http://investorshangout.com/post/view?id=1835...z3A5gmzrTx
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 219

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 235

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 272

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
7th World Media Summit Spotlights Media's Future in Beijing

Updated Category News Views 235

The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 183

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 347

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
JOYEE N01 Kicks Off Global Launch with African Orders

Updated Category News Views 319

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 365

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 468

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 314

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading

Top 5 Most Recently Viewed Articles

Affordable Technology Solutions with Human-I-T's Initiative

Updated Category News Views 184

Human-I-T Launches 'Get It Done' Initiative to Bridge Digital Divide Human-I-T has unveiled its new 'Get It Done' Initiative aimed at making essential technology accessible to everyone without straining their finances. This program focuses on providing quality refurbished laptops at an affordable price, ensuring that individuals and families can benefit from reliable...

Continue Reading
Jasper Street Launches Activism Defense Practice with New Partners

Updated Category News Views 125

Jasper Street Partners Strengthens Activism Defense Practice Jasper Street Partners is gearing up to enhance its defense against activist investors by bringing on board two experienced bankers. Their main objective is clear: to assist clients in identifying weaknesses, navigating proxy contests, and managing the pressures that come with public activism. Introducing New...

Continue Reading
Royalty Pharma's $300 Million Partnership with Zenas BioPharma

Updated Category News Views 139

Funding Agreement for Obexelimab Development Royalty Pharma plc and Zenas BioPharma, Inc. have joined forces in a groundbreaking funding agreement that could inject up to $300 million into the development of obexelimab, a promising treatment for autoimmune diseases, specifically IgG4-Related Disease (IgG4-RD). This alliance highlights Royalty Pharma’s commitment to...

Continue Reading
KBR, Inc. Shares Drop Significantly Following Contract News

Updated Category News Views 242

Significant Decline in KBR, Inc. Shares KBR, Inc. (NYSE: KBR) recently faced a substantial decline in its stock value. This shift came after the announcement regarding the termination of a key contract, leaving many investors anxious about the company's future prospects. The market reacted sharply, indicating the level of uncertainty surrounding KBR's operations and...

Continue Reading
Dr. Mike Varshavski to Address Medical Misinformation Soon

Updated Category News Views 407

Dr. Mike Varshavski to Discuss Medical Misinformation The National Press Club is set to host a compelling event featuring Dr. Mikhail "Dr. Mike" Varshavski, a well-known physician and a social media phenomenon. This exciting Headliners event will take place soon, and attendees can expect an engaging dialogue focused on vital issues surrounding medical misinformation and...

Continue Reading